A diabetes mellitus kórismézéséről, a cukorbetegek antihyperglykaemiás kezeléséről és gondozásáról felnőttkorban

Objectives

This Hungarian professional guideline provides an evidence-based, sector-neutral framework for screening, diagnosing, preventing, treating and providing lifelong follow-up care for diabetes mellitus in adults, including type 1, type 2, other specific forms and gestational diabetes. It seeks to improve care quality through individualised, patient-centred decisions that combine scientific evidence, clinical judgement, patient preferences and the characteristics of the Hungarian health system.[1][2]Its central clinical aim is to achieve safe metabolic control, usually with an HbA1c target below 7.0% within an individualised 6.0% to 8.0% range, to prevent or slow microvascular and macrovascular complications while avoiding hypoglycaemia and respecting age, comorbidity, life expectancy and personal circumstances.[3][4][5]

• Strengthen prevention of type 2 diabetes through risk identification, FINDRISC-based screening, laboratory assessment, lifestyle support and, for selected people with prediabetes, consideration of metformin alongside lifestyle therapy.[6][7][8][9]
• Establish accurate diagnosis and classification using laboratory venous-plasma glucose, oral glucose tolerance testing and standardised HbA1c testing, with confirmation of abnormal findings in asymptomatic people and classification by diabetes aetiology rather than current treatment.[10][11][12]
• Deliver person-centred treatment that integrates nutrition therapy, physical activity, self-management education, glucose-lowering medicines, insulin, monitoring technologies and, in selected cases, bariatric surgery or transplantation.[13][14][15][16][17]
• Prioritise cardiovascular and renal risk reduction, including treatment choices informed by cardiovascular disease, heart failure, chronic kidney disease, estimated glomerular filtration rate and affordability.[18][19][20]
• Provide specialised pathways for pregnancy, including preconception care, gestational-diabetes screening, maternal glycaemic management, postpartum reclassification and continuing follow-up.[21][22][23]
• Prevent complications and sustain quality of life through regular care, structured education, self-monitoring, nutrition and weight management, physical activity, and timely treatment adjustment.[24][25][26]

Implementation

The guideline is implemented as clinical decision support rather than a substitute for professional judgement: departures may be made where justified and documented.[1][27]It adapts international recommendations, principally from the American Diabetes Association and European Association for the Study of Diabetes, to Hungarian care conditions, using evidence appraisal and consensus-based recommendation development.[28][29]Care is delivered across primary care, specialist outpatient services, diagnostics and inpatient settings, with general practitioners leading routine type 2 diabetes management and specialist services supporting type 1 diabetes, insulin-treated or complicated cases, pregnancy and advanced complications.[2][24][30]

• Coordinate guideline development through the Hungarian Health Professional College’s Internal Medicine, Endocrinology, Diabetes and Metabolic Diseases section, with multidisciplinary contributors and review by relevant professional sections; the Hungarian Diabetes Association participated as a professional society with consultation rights.[31][32]
• Apply evidence levels and recommendation grades based on the American Diabetes Association framework, integrating randomised trials, meta-analyses, observational evidence, expert consensus and clinical experience.[33][34]
• Deliver diabetes care through multidisciplinary teams that may include diabetologists, general practitioners, diabetes specialist nurses or educators, dietitians, psychologists and relevant specialty clinicians.[35][24][30]
• Use shared decision-making to select treatment according to glycaemia, complications, cardiovascular and renal status, body weight, hypoglycaemia risk, social circumstances, patient preferences, capacity for self-management and ability to meet treatment costs.[19][36][37]
• Embed structured education from diagnosis onwards, including dietary counselling, medication use, insulin injection where needed, self-monitoring skills, lifestyle management and review of adherence at consultations.[38][25][26]
• Support monitoring through regular HbA1c measurement, glucose self-monitoring, annual retinal, renal, neuropathy, foot, cardiovascular and physical assessments, and comprehensive laboratory review.[25][39]
• Use process indicators for quality improvement, including four annual HbA1c measurements for insulin-treated patients, two for patients not treated with insulin, self-monitoring by 90% of insulin-treated patients, and annual renal laboratory monitoring for 100% of patients.[39]
• Review the guideline at the end of its validity period, with earlier exceptional review when major changes in evidence or the care environment warrant it; the Professional College section monitors literature and domestic care conditions.[39][40]
• Recognise financing constraints: the 2011 National Diabetes Programme was accepted without allocated resources, reimbursable diabetes follow-up was described as underfinanced, and patient education lacked financing.[41][42]

Monitoring & Evaluation

The guideline combines clinical monitoring, screening, service-quality measurement and evidence review. It specifies patient-level measures for diagnosis, treatment adjustment and complication prevention, alongside a limited set of process indicators for assessing diabetes-care quality; it does not establish a national reporting system, surveillance body or formal accountability process.[39][40]

• Monitor population burden through prevalence, incidence, age and sex distribution, screening findings and numbers receiving antidiabetic treatment. Hungary has no central diabetes register, limiting the precision of national prevalence estimates.[43][44][45]
• Screen adults at risk using the Finnish Diabetes Risk Score followed by laboratory testing, oral glucose tolerance testing or glycated haemoglobin measurement as appropriate. Repeat negative screening every three years for people aged 45 years or over, annually for people with prediabetes, and every one to two years after gestational diabetes where post-partum testing is negative.[6][7][8]
• Assess diagnosis through standardised venous plasma glucose, oral glucose tolerance testing and laboratory glycated haemoglobin measurement; confirm abnormal results in asymptomatic people through repeat concordant testing.[10][46][11]
• Review glycaemic management through individually agreed glycated haemoglobin targets, generally below 7.0% within an individual range of 6.0% to 8.0%, and usually reconsider treatment after about three months if the target is not met.[5][36][47]
• Monitor renal and cardiovascular risk through estimated glomerular filtration rate, albuminuria, blood pressure, lipid values and relevant cardiovascular, heart-failure and kidney endpoints.[18][48][49]
• Use self-monitoring of blood glucose according to diabetes type, treatment regimen and hypoglycaemia risk; use continuous glucose-monitoring data, where available, to assess average glucose, time in hypoglycaemic, target and hyperglycaemic ranges, and the glucose management indicator.[50][51][52][53]
• Conduct routine follow-up according to diabetes type, treatment and complications, with typical reviews four to six times annually for type 1 diabetes and two to four times annually for non-insulin-treated type 2 diabetes. Measure weight, waist circumference, body mass index, blood pressure and glucose at consultations, and undertake annual eye, foot, laboratory and treatment reviews.[25]
• Apply pregnancy-specific monitoring, including glucose testing at defined gestational stages, postpartum oral glucose tolerance testing, and retinal assessment in every trimester and one year after delivery for women with pre-existing diabetes.[22][54][23][55]
• Monitor weight-management interventions through nutritional assessment at every diabetes consultation, regular weight checks and monthly long-term reviews where weight-loss treatment continues.[56][57]
• Use long-term outcome measures, including end-stage renal failure, blindness, lower-limb amputation, myocardial infarction and stroke, alongside intermediate measures such as retinopathy, foot lesions, albuminuria, estimated glomerular filtration rate, glycated haemoglobin, hypoglycaemia, ketoacidosis, lipids, blood pressure and anthropometry. These outcomes require long-term interpretation and are not considered direct care-quality indicators because multiple factors beyond provider control affect them.[58][39]
• Assess care quality through process indicators: four annual glycated haemoglobin measurements for insulin-treated patients and two for non-insulin-treated patients; self-monitoring among 90% of insulin-treated patients; and annual comprehensive laboratory monitoring, foot inspection, neuropathy assessment, physical examination and dietary education for newly diagnosed patients at stated desired levels.[39]
• Maintain annual retinal examination and electrocardiography at desired coverage of 90%, and annual microalbuminuria and estimated glomerular filtration rate assessment at 100% desired coverage.[39]
• Review the guideline at expiry, with earlier exceptional review where major changes in evidence or the care environment warrant it. The Professional College’s Internal Medicine, Endocrinology, Diabetes and Metabolic Diseases section or council is responsible for monitoring literature and domestic care conditions.[39][40]

Costing & Financing

The guideline contains limited quantified financial information. It recognises diabetes as a substantial economic burden, identifies affordability and reimbursement as factors in treatment selection, and records important funding constraints in Hungarian diabetes services; it does not provide a comprehensive implementation budget, costing methodology, national financing envelope or quantified funding gap.[59][19][41][42]

• Recognise global diabetes-related health expenditure of 760 billion US dollars in 2019, a reported 4.5% increase since 2017.[59]
• Consider patient affordability, medicine cost and applicable reimbursement rules when selecting glucose-lowering treatment.[60][61][62]
• Use lower-cost-oriented options, including metformin combined with a sulfonylurea or human insulin, where financial difficulty constrains treatment choice.[63][64]
• Note that metformin is supported partly by its favourable price, while glucagon-like peptide-1 receptor agonists are characterised as imposing the greatest patient treatment burden among the listed medicine classes.[65][66]
• Apply national financing rules for kidney-protective treatment. As of December 2019, patients selecting sodium-glucose cotransporter-2 inhibitor monotherapy in Hungary paid the full price.[67][68]
• Support insulin-pump acquisition through social health insurance, with replacement after the four-year service period dependent on demonstrated treatment effectiveness.[69]
• Provide continuous glucose monitoring to eligible people with type 1 diabetes through enhanced 98% support or normative 80% support from 2020.[70][71]
• Recognise genetic testing for monogenic diabetes as expensive but potentially cost-effective; no monetary estimate is provided.[13]
• Recognise bariatric surgery as costly and associated with operative risk, but note that no procedure price, budget or funding arrangement is specified.[72]
• Address financing constraints affecting implementation of the 2011 National Diabetes Programme: the authority agreed with the programme but could not allocate financial resources. Reimbursable diabetes follow-up was described as low-financed, potentially leaving independently operating specialist services loss-making, while patient education was described as unfunded.[41][42]
• Include diabetes self-management education among activities supported by the institution or insurer responsible for patient care; the source provides no quantified allocation.[26]